[Experimental study of bone infection on WO-1 controlled-release system]

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Infectious Disease Research

Context:

• Bone defects and infections pose significant clinical challenges.
• Current bone graft materials lack inherent anti-infective properties.
• Developing materials with integrated antimicrobial functions is crucial for improving patient outcomes.

Purpose:

• To engineer a novel bio-derived bone material with enhanced anti-infective capabilities.
• To incorporate and control the release of an antimicrobial agent (WO-1) within a collagen-based bone scaffold.
• To evaluate the material's efficacy in vitro and in vivo.

Summary:

• A collagen-loaded, bio-derived bone material was fabricated using type-I collagen and allograft bone, with the antimicrobial agent WO-1 incorporated.
• Scanning electron microscopy confirmed the material's porous structure coated with collagen.
• In vitro studies demonstrated sustained release of WO-1 and significant bacteriostasis against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
• In vivo studies in rabbits showed sustained WO-1 concentrations in bone and muscle tissue with minimal systemic presence, alongside effective bacteriostasis.

Impact:

• This innovative bone graft material offers a promising solution for preventing and treating bone infections.
• The controlled drug release mechanism enhances therapeutic efficacy and reduces the risk of antimicrobial resistance.
• Successful translation could lead to improved surgical outcomes and reduced healthcare costs associated with bone infections.